Artgen Biotech PJSC (MIC:ABIO) Long-Term Capital Lease Obligation : ₽124 Mil (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Long-Term Capital Lease Obligation?

Artgen Biotech PJSC's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₽124 Mil.

Artgen Biotech PJSC's quarterly Long-Term Capital Lease Obligation increased from Jun. 2022 (₽109 Mil) to Dec. 2022 (₽111 Mil) and increased from Dec. 2022 (₽111 Mil) to Jun. 2023 (₽124 Mil).

Artgen Biotech PJSC's annual Long-Term Capital Lease Obligation declined from Dec. 2020 (₽126 Mil) to Dec. 2021 (₽114 Mil) and declined from Dec. 2021 (₽114 Mil) to Dec. 2022 (₽111 Mil).

Artgen Biotech PJSC Long-Term Capital Lease Obligation Historical Data

The historical data trend for Artgen Biotech PJSC's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Long-Term Capital Lease Obligation Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.59

134.19

125.59

113.82

111.36

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															119.11	113.82	108.67	111.36	123.60

Artgen Biotech PJSC (MIC:ABIO) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Artgen Biotech PJSC Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.